NCT07091227View on ClinicalTrials.gov

Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

July 20, 2026

Study Completion Date

July 20, 2029

Conditions
Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

AK112+oxaliplatin+capecitabine

participants will receive standard dose treatment of AK112 combined with oxaliplatin+capecitabine every 3 weeks for 4 cycles before surgery.

DRUG

oxaliplatin+capecitabine

participants will receive standard dose treatment of oxaliplatin+capecitabine every 3 weeks for 4 cycles before surgery

Trial Locations (1)

100730

Department of Cancer Medical Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing

All Listed Sponsors
collaborator

Akeso Biopharma Co., Ltd.

UNKNOWN

lead

Peking Union Medical College Hospital

OTHER